DDR2-CAR-M

DDR2-CAR-M is an experimental chimeric antigen receptor (CAR) macrophage therapy designed to target discoidin domain receptor 2 (DDR2), a protein highly expressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment. By specifically targeting and eliminating or reprogramming CAFs, DDR2-CAR-M aims to disrupt the immunosuppressive extracellular matrix (ECM) that typically excludes immune cells from solid tumors. The therapy utilizes adenoviral transduction to engineer primary macrophages, which then polarize toward a pro-inflammatory M1 phenotype. Preclinical evidence suggests that DDR2-CAR-M can normalize tumor vasculature, enhance antigen presentation, and increase the infiltration of CD8+ T cells and dendritic cells, effectively converting immunologically cold tumors into hot ones. It has shown efficacy in murine models of lung cancer, colorectal cancer, and glioblastoma.

Other names

DDR2-targeted chimeric antigen receptor macrophagesDDR-2-targeted chimeric antigen receptor macrophagesDDR 2-targeted chimeric antigen receptor macrophagesDDR2-CAR macrophagesDDR-2-CAR macrophagesDDR 2-CAR macrophages